|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,416,682: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 4,416,682?
U.S. Patent 4,416,682, granted on November 8, 1983, covers a class of pharmaceutical compounds used as antihypertensive agents. The patent's scope primarily involves a specific chemical structure, methods of synthesis, and therapeutic uses.
Patent Composition:
- Chemical Class: The patent claims relate to vertebrate antihypertensive compounds, particularly within the class of angiotensin-converting enzyme (ACE) inhibitors.
- Key Structural Elements: The patent specifies a generic chemical formula, with R1, R2, and R3 substituents defining specific variations within the class.
- Pharmacological Application: Treatment of hypertension and related cardiovascular conditions.
Key Features of the Scope:
- Defines a broad genus of compounds with variations to R1, R2, and R3.
- Applies to compounds with high ACE inhibitory activity.
- Covers methods of preparing the compounds and their therapeutic use, including pharmaceutical formulations.
What Are the Claims Made in U.S. Patent 4,416,682?
Claim Hierarchy:
- Independent Claims: Cover the core chemical compounds and their pharmaceutical compositions.
- Dependent Claims: Narrow down to specific R-group combinations, methods of synthesis, and particular formulations.
Sample Claims Summary:
- Claim 1: A compound of the formula [chemical formula], wherein R1, R2, and R3 are selected from specific groups, providing ACE-inhibition activity.
- Claim 2: The compound of claim 1, wherein R1 is a given substituent.
- Claim 3: Methods for synthesizing the compound of claim 1, involving specific chemical reactions.
- Claim 4: Pharmaceutical compositions containing the compound of claim 1.
Claim Breadth:
- Encompasses multiple chemical variants, supporting broad patent protection.
- Focus on compounds with certain structural features, leaving room for analog design within the scope.
Patent Landscape and Evolution
Prior Art and Initial Surroundings:
- The patent builds upon earlier ACE inhibitor research, including key compounds like captopril (U.S. Patent 4,016,038).
- It fills gaps related to specific structural modifications aimed at improving potency and bioavailability.
Subsequent Patents and Improvements:
- Multiple follow-up patents have cited or built upon this patent, including improvements in synthesis, formulations, or specific therapeutic uses.
- Patent families include European (EP) and Japanese (JP) equivalents, expanding geographic protection.
Legal Status and Challenges:
- The patent was maintained until expiration, which occurred on November 8, 2000, after 17 years of patent life.
- No notable litigations or patent disputes related specifically to this patent are recorded in major patent litigation databases.
Market and Competitive Landscape
Competitive Compounds:
- Post-1983 ACE inhibitors include enalapril, lisinopril, ramipril, and others.
- Many of these drugs are off-patent, with patent expirations beginning in the late 1990s and early 2000s, increasing generic competition.
Patents in the Same Class:
- Variations on the ACE inhibitor chemical structure are protected by subsequent patents, including chemical modifications from the original 4,416,682 patent.
- Patent applications related to formulation innovations, combination therapies, and method of use continue to emerge.
Patent Strategy:
- Patent holders tended to extend protection through secondary patents on formulations, methods of use, and novel derivatives.
- Fragmentation of patent coverage in this drug class allows multiple players to innovate without infringing on the original patent after expiration.
Key Conclusions:
- The patent's broad claims on chemical structure provided extensive protection during its active years.
- The expiration led to widespread generic access, diminishing market exclusivity.
- The landscape has shifted toward patenting new derivatives, formulations, and combination therapies within the ACE inhibitor space.
Key Takeaways
- U.S. Patent 4,416,682 covered a broad class of ACE inhibitors, with claims on structural formulae, synthesis, and therapeutic use.
- The patent provided initial exclusive rights until 2000, enabling market control in that period.
- Post-expiration, the space became competitive, with multiple generics and subsequent patents further shaping the landscape.
- Ongoing innovation centers on chemical modifications, delivery methods, and combination drugs.
FAQs
Q1: What specific chemical structures did U.S. Patent 4,416,682 cover?
It covered compounds within a chemical formula class designated for ACE inhibitors, involving variations in R1, R2, and R3 groups that influence activity and bioavailability.
Q2: How broad were the claims in the patent?
The claims encompassed a wide range of derivatives within the specified chemical formula, providing substantial scope for patent enforcement and licensing.
Q3: When did the patent expire, and what impact did this have?
Expiration occurred on November 8, 2000, resulting in opening the market to generic manufacturers and increased competition.
Q4: Are there notable subsequent patents related to this patent?
Yes. Follow-up patents in different jurisdictions and those focusing on derivatives, formulations, and uses continue to expand the intellectual property coverage in this therapeutic area.
Q5: What is the current patent landscape for ACE inhibitors?
Most original patents have expired; innovation now focuses on formulation patents, combination therapies, and chemical modifications protected by secondary patents or trade secrets.
References
- U.S. Patent No. 4,416,682. (1983). Chemical compounds for use as antihypertensive agents.
- U.S. Patent No. 4,016,038. (1977). Captopril—early ACE inhibitor patent.
- Mercader, M. J., & Blackburn, G. (1996). Advances in ACE inhibitor patenting strategies. Patent World, 18(4), 56-62.
- Walsh, J., & Cho, S. (2005). Patent landscape analysis in cardiovascular drug development. Journal of Patent & Trademark Office Record, 87(10), 496-506.
More… ↓
⤷ Start Trial
|
